Table 1.
The main baseline characteristics of each included trial considered in this meta-analysis
| Study | TMB-evaluable patients, n (%) | Treatment arm | Number of patients | Detection method | Threshold defined | Sample |
|---|---|---|---|---|---|---|
| KEYNOTE-04228 | 793/1274 (62.2) | Pembrolizumab versus CT | 180 versus 165 (TMB-high); 234 versus 214 (TMB-low) | WES | 175 mut/exome | Tissue |
| CheckMate 227 part 131-210 | 679/1166 (58.2) | Nivolumab + ipilimumab versus CT | 139 versus 160 (TMB-high); 191 versus 189 (TMB-low) | NGS (FoundationOne®CDx) | 10 mut/mb | Tissue |
| CheckMate 02613 | 312/541 (57.6) | Nivolumab versus CT | 47 versus 60 (TMB-high); 111 versus 94 (TMB-low) | WES | 243 missense mut | Tissue |
| MYSTIC32 | 315/744 (42.3) | Durvalumab + tremelimumab versus CT | 60 versus 67 (TMB-high); 104 versus 84 (TMB-low) | NGS (FoundationOne®CDx) | 10 mut/Mb | Tissue |
| MYSTIC32 | 296/746 (39.6) | Durvalumab versus CT | 60 versus 67 (TMB-high); 85 versus 84 (TMB-low) | NGS (FoundationOne®CDx) | 10 mut/Mb | Tissue |
| MYSTIC32 | 523/744 (70.2) | Durvalumab + tremelimumab versus CT | 64 versus 70 (TMB-high); 204 versus 185 (TMB-low) | NGS (Guardant OMNI®) | 20 mut/Mb | Blood |
| MYSTIC32 | 541/746 (72.5) | Durvalumab versus CT | 77 versus 70 (TMB-high); 209 versus 185 (TMB-low) | NGS (Guardant OMNI®) | 20 mut/Mb | Blood |
| IMpower11033 | 389/554 (70.2) | Atezolizumab versus CT | 87 (TMB-high); 302 (TMB-low) | NGS (FoundationOne®CDx) | 16 mut/Mb | Blood |
CT, platinum-based chemotherapy; Mb, megabase; mut, mutations; NGS, next-generation sequencing; TMB, tumor mutational burden; WES, whole-exome sequencing.